1. Introduction {#sec1}
===============

Differentiated thyroid carcinoma (DTC) require lifelong monitoring as approximately 20% of patients recur \[[@bib1], [@bib2]\]. Whole body iodine scintigraphy (WBS) is an effective method of localizing the source of rising thyroglobulin levels (Tg). However, in the scenario of a negative WBS, localizing non-iodine-avid lesions is essential to adequate therapy \[[@bib1], [@bib3], [@bib4]\].

Most of the patients with DTC have a benign evolution and treatment response. However, as thyroid cancers become more aggressive, they develop a reduction of the sodium iodide symporter and overexpression of the GLUT1 transporter, thus becoming radioiodine refractory (RAIR). The RAIR presentation accounts for approximately 2% of all DTC patients and thus studies in this population tend to have small samples, even in multicentric studies \[[@bib5], [@bib6]\]. In consequence, these cancers develop an overexpression of the GLUT1 transporter and tend to concentrate F-18 FDG. F-18 FDG PET/CT (FDG PET/CT) has been able to improve the diagnostic work-up of patients with a negative WBS and elevated Tg levels \[[@bib7], [@bib8]\].

Although elevated TSH levels (*e*TSH) increase the sensitivity for recurrent or metastatic DTC in WBS this increased sensitivity is not necessarily required in FDG PET/CT images in patients with RAIR \[[@bib9]\]. Some studies have shown that FDG PET/CT may be more accurate to detect RAIR recurrence under *e*TSH \[[@bib10], [@bib11]\]. However, others have not been able to demonstrate the clear benefit or additive role of *e*TSH \[[@bib12], [@bib13], [@bib14], [@bib15], [@bib16]\]. Therefore there is no convincing evidence that *e*TSH increases the sensitivity of FDG PET/CT imaging in RAIR, mainly due to lack of studies within the same patient and/or represented by a limited number of patients \[[@bib16], [@bib17], [@bib18]\].

The purpose of this study was to prospectively compare in RAIR DTC patients the uptake pattern of FDG PET/CT within the same patient in two different conditions: with elevated TSH levels (*e*TSH) *versus* suppressed TSH levels (*s*TSH).

2. Materials and methods {#sec2}
========================

2.1. Study design {#sec2.1}
-----------------

All patients that participated in the study with histology-proven differentiated thyroid cancer (DTC) gave written consent prior to enrollment (between July 2013 and January 2017). The institution\'s ethics committee and review board approved the study (CAAE: 18759313.0.0000.5404).

2.2. Inclusion and exclusion criteria {#sec2.2}
-------------------------------------

DTC patients under 18 years old, pregnant and/or breast-feeding or with clinical morbidity that contraindicated levothyroxine (T~4~) withdrawal, were excluded.

DTC patients that had undergone total thyroidectomy plus central neck dissection and at least one cycle of I-131 therapy were included if presenting sings of RAIR cancer: increasing serum Tg levels (with suppressed Tg levels above 1 ng/ml and/or stimulated Tg levels above 10 ng/ml) or increasing Tg antibodies (ATg) levels.

2.3. Suppressed TSH levels (*s*TSH) and elevated TSH levels (*e*TSH) {#sec2.3}
--------------------------------------------------------------------

Suppressed TSH levels (*s*TSH) were considered suppressed when below 1 μIU/L. After a 30-day hormonal withdrawal period the TSH levels were considered elevated (*e*TSH) when above 40 μIU/L.

All DTC patients underwent FDG PET/CT imaging in these two different conditions of TSH levels. Blood samples were obtained in the morning prior to all of the F-18 FDG doses administered.

Ninety days after the end of all imaging studies, new blood samples of suppressed Tg and ATg levels were obtained. These were required in order to compare the suppressed Tg levels obtained prior to the first suppressed Tg levels, before commencing the protocol. This was done in order to exclude disease progression between *s*TSH and *e*TSH FDG PET/CT studies.

2.4. F-18 FDG PET/CT acquisition {#sec2.4}
--------------------------------

FDG PET/CT images were performed following intravenous administration of 3.7 MBq/kg (0.1 mCi/kg) of F-18 FDG after fasting for at least 6 h and with serum glucose levels below 150 mg/dl.

After the 60-minute F-18 FDG uptake time, images were acquired on a PET/CT (SIEMENS Biograph mCT-True Point--TOF-full HD, Erlangen, Germany) from the base of the skull to the mid-thigh.

The 3D PET scan was acquired at 90 seconds/bed using a 512 × 512 pixels matrix (pixel size = 1 mm). The CT scan was performed with 80 mA, 120 Kv. Images were reconstructed by a true X + TOF (ultra HD; two iterations and twenty-one subsets) and displayed in 3.5mm slices on dedicated workstations.

2.5. F-18 FDG PET/CT image analyses {#sec2.5}
-----------------------------------

Two different groups composed of one radiologist and one nuclear medicine physician blindly evaluated the PET, CT and fused images available in axial, coronal and sagittal planes as well in three-dimensional cine mode.

The groups recorded the number and site of lesions and the SUVmax of each lesion. Lesions were classified as follows: local recurrence, cervical lymph node (LN) metastases, distant LN metastases, lung metastases, bone metastases or other sites. When there were more than ten lesions in each site they were classified as above ten (\>10).

PET/CT studies were visually and quantitatively evaluated (SUVmax). We reported all suspicious sites of focal F-18 FDG uptake, considering the lesion contrast with background.

2.6. Reference standard {#sec2.6}
-----------------------

All imaging methods available (neck ultrasound (US), CT and MRI); any biopsy when possible and clinical follow-up with consensus among investigators in the end of the study were used as the reference standards. The reference standard was compared to the findings of the FDG PET/CT images obtained under *e*TSH and under *s*TSH levels.

2.7. Statistical analysis {#sec2.7}
-------------------------

Each set of patient images (*e*TSH FDG PET/CT *versus s*TSH FDG PET/CT) were compared considering number of lesions regarding local recurrence, cervical and distant lymph node metastases, and metastases in the lungs, bones and other sites.

Patient and clinical characteristics were summarized using descriptive statistics. Frequencies and percentages were provided for categorical variables; meanwhile, standard deviation (SD), mean, median and range were provided for continuous variables.

The Wilcoxon test was used to compare the SUVmax values and number of metastases between both studies because our sample is small and due to this fact, the distribution was not normal. When the quantity of variables analyzed were equal or under two the Wilcoxon test could not be calculated (NC). Therefore this test could not be applied for a completeness of the data.

The kappa coefficient was used to compare the agreement between F-18 FDG PET/CT studies performed in different moments (with *e*TSH versus *s*TSH). The significance level was 5%.

3. Results {#sec3}
==========

Seventeen patients with DTC (mean time of diagnosis = 9.7 ± 4.3 years) were included. Among these, two patients were excluded. One patient was excluded because radioiodine (^131^I) therapy was performed between the *s*TSH and *e*TSH FDG PET/CT studies; and the other patient requested to be removed from the study. Fifteen patients with DTC were eligible for analysis (12 women; 55.7 ± 16.2 years old) ([Table 1](#tbl1){ref-type="table"}).Table 1Patient characteristics prior to enrollment.Table 1Patient (N = 15)AgeSexTime of cancer\
DiagnosesSubtypeStageSurgeryI-131 cumuative\
Dose (mCi)*s*Tg prior to F-18 FDG PET/CT173F8NAIIITT440217273M9NAIIIUND82869375F17NAIIIBND12184500470M8AIIUND4202856559F8AIIIBND5504500676F18AIIITT10664.40747F7NAITT12241214860F11AIIITT70016.70937F15NAIBND3504.60∗1036F9AIUND1501.27∗1145M6AITT1620.20∗1241F7AITT1720.40∗1346F9NAIUND1500.74∗1467F12AIIITT2009.251531F2AITT1530.20∗Mean55.7-9.7\-\--518892.9S.D.16.2-4.3\-\--3971596.3[^1]

All patients had undergone total thyroidectomy and central neck dissection. DTC of non-aggressive subtype was identified in 40% of the patients (classic, follicular, and mixed-papillary and follicular variants) while the aggressive ones were found in 60% of the patients (tall cell, columnar cell, diffuse sclerosing, solid/trabecular, or insular variants).

Approximately 50% of the patients were initially diagnosed as stage I (7/15) and the other half in stage III (7/15). Only one patient was diagnosed as having a stage II cancer and none had stage IV disease at initial staging.

The mean cumulative ^131^I dose was 19.1 ± 14.6 GBq (518 ± 397 mCi) ([Table 1](#tbl1){ref-type="table"}) and the mean clinical follow-up period was 3.5 years.

The time interval between *s*TSH and *e*TSH FDG PET/CT images was 57 ± 105 days (range 27--202 days; median = 56 days). The elevation of serum TSH levels after T~4~ withdrawal at the time of the FDG PET/CT acquisitions was appropriate: *e*TSH levels were significantly higher (p = 0.0001) than *s*TSH levels ([Table 2](#tbl2){ref-type="table"}). Likewise, stimulated Tg levels (obtained with *e*TSH) were significantly higher (p = 0.001) than suppressed Tg levels (obtained with *s*TSH) ([Table 2](#tbl2){ref-type="table"}). In addition, for all patients, there were no laboratory signs of progression between FDG PET/CT exams because no differences between the serum *s*TSH and *s*Tg of all patients prior to and 90 days after the last FDG PET/CT were found ([Table 3](#tbl3){ref-type="table"}). *e*TSH and *e*Tg were not collected prior beginning the study and 90 days after the last FDG PET/CT because the endocrinologists' team were not comfortable to submit the patients to three thyroxin withdrawal (prior beginning the study, for the *e*TSH FDG PET/CT study and another time submitting patients to a new *e*TSH 90--120 days after the last PET/CT). That is the reason why there are no data for *e*TSH and *e*Tg in [Table 3](#tbl3){ref-type="table"}.Table 2Blood serum levels of TSH, Tg and At in patients undergoing F-18 FDG PET/CT with suppressed and elevated TSH levels.Table 2sTSH\
F-18 FDG PET/CTeTSH\
F-18 FDG PET/CT*p-values*MeanSDMeanSDTSH (μIU/L)0.40.6129.877.6**\<0.0001∗**Tg (ng/mL)892.91652.31226.11783.0**0.001∗**ATg (IU/mL)320.31028.1314.81028.40.750[^2]Table 3Serum *s*TSH and *s*Tg values obtained for all patients prior to and 90 days after the last F-18 FDG PET/CT study.Table 3Serum levels prior to F-18 FDG PET/CT studiesSerum levels 3 months after F-18 FDG PET/CT studies*p-values*MeanSDMeanSDsTSH (μIU/L)0.150.210.260.300.3101sTg (ng/mL)892.921652.34893.451630.180.6772[^3][^4]

Previous imaging studies (WBS, US or CT) were negative in 9/15 (60%) despite of increasing thyroglobulin levels. FDG PET/CT detected sites of metastases in 12/15 (80%) patients with *e*TSH and *s*TSH images. In the three remaining patients (20%) neither *e*TSH nor *s*TSH FDG PET/CT studies detected metastases; in two of these three patients, the reference pattern showed stable disease ([Table 4](#tbl4){ref-type="table"}).Table 4Lesion identification on imaging work-up prior to and after F-18 FDG PET/CT studies and comparison to reference standard and clinical follow-up.Table 4Patient (N = 15)Lesion identification on imaging work-up prior to F-18 FDG PET/CTAdditional findingsReference StandardFollow up*s*TSH\
F-18 FDG PET/CT*e*TSH\
F-18 FDG PET/CT1LungDLn\
Lung\
BoneDLn\
Lung\
BoneDLn\
Lung\
BoneProgression2LungLungCLn\
LungDLn\
LungProgression3LungCLn\
Lung\
BoneCLn\
Lung\
Bone\
OtherCLn\
Lung\
BoneProgression4LungDLn\
LungCLn\
DLn\
LungLR\
CLn\
DLn\
LungProgression5CLn\
LungLR\
CLn\
Lung\
BoneLR\
CLn\
Lung\
BoneLR\
CLn\
Lung\
BoneProgression6NINININIStable7NILungCLn\
LungCLn\
LungProgression8CLnCLn\
LungCLn\
DLn\
LungCLn\
DLn\
LungProgression9NININICLnStable10NININICLnProgression11NICLnCLnLR\
CLnProgression12NICLnCLnCLnProgression13NICLn\
DLnCLn\
DLnLR\
CLn\
DLnProgression14NILRLRLR\
CLnProgression15NICLn\
OtherCLn\
OtherCLnProgression[^5][^6]

*e*TSH FDG PET/CT presented higher sensitivity (**S**), compared to *s*TSH for cervical lymph nodes (**S**: 75% *vs* 50%) and for distant lymph nodes (**S**: 80% *vs* 60%); probably due to the trend in SUVmax rising (p = 0.750). Both *e*TSH and *s*TSH FDG PET/CT studies had high specificity and accuracy, especially for detection of lung, bone and other metastases ([Table 5](#tbl5){ref-type="table"}).Table 5Imaging performance of *s*TSH and *e*TSH F-18 FDG PET/CT studies compared to reference standards.Table 5Sites of metastases*s*TSH F-18 FDG PET/CT*e*TSH F-18FDG PET/CTSensitivitySpecificityAccuracySensitivitySpecificityAccuracyLocal recurrence40%100%80%40%100%80%Cervical lymph nodes50%100%60%75%100%80%Distant Lymph nodes60%100%87%80%100%93%Lung100%100%100%100%100%100%Bone100%100%100%100%100%100%Others-93%93%-87%87%Mean58%99%87%66%98%90%[^7]

3.1. Local recurrence {#sec3.1}
---------------------

Both the *eTSH* ^FDG^ PET/CT and *sTSH* FDG PET/CT images identified local recurrence in 13% of the patients; a strong correlation (kappa = 1) was noted between both studies ([Table 6](#tbl6){ref-type="table"}).Table 6Per-patient analysis of *s*TSH and *e*TSH F-18 FDG PET/CT images for detecting metastases.Table 6Sites of metastases*s*TSH\
F-18 FDG PET/CT\
N (%)*e*TSH\
F-18 FDG PET/CT\
N (%)*Kappa*Local recurrence2 (13)2 (13)1Cervical LNs7 (47)10 (67)0.6087Distant LNs3 (20)4 (27)0.8148Lung7 (47)7 (47)1Bone2 (13)2 (13)1Other1 (7)2 (13)0.8865[^8]

Because of the small number of cases, on a per-lesion basis and in the SUVmax analysis, the *e*TSH ^FDG^ PET/CT presented a not calculable difference compared to *s*TSH FDG PET/CT (N ≤ 2) ([Table 7](#tbl7){ref-type="table"}).Table 7Per-lesion analysis of *s*TSH and *e*TSH F-18 FDG PET/CT images for detecting metastases.Table 7Sites of metastases*s*TSH\
F-18 FDG PET/CT\
Mean ± SD*e*TSH\
F- 18 FDG PET/CT\
Mean ± SDp-valuesLocal recurrence0.13 ± 0.350.13 ± 0.35NCCervical LNs2.3 ± 2.91.73 ± 1.711Cervical LN levels0.9 ± 1.23.7 ± 3.90.1250Distant LNs0.6 ± 1.80.3 ± 0.61Lung1.3 ± 1.41.3 ± 1.41Bone0.1 ± 0.30.1 ± 0.3NCOther0.1 ± 0.30.1 ± 0.3NCTotal lesions4.5 ± 3.53.6 ± 3.90.3203[^9]

3.2. Cervical and distant lymph node metastases {#sec3.2}
-----------------------------------------------

The detection rate of *e*TSH FDG PET/CT scans were higher and identified cervical lymph node metastases in 67% of the patients while in the *s*TSH FDG PET/CT scans, cervical lymph node metastases were identified in only 47% of the patients. However, a high agreement (kappa = 0.6087) was noted among the studies ([Table 6](#tbl6){ref-type="table"}) ([Figure 1](#fig1){ref-type="fig"}).Figure 1*e*TSH PET/CT images demonstrated uptake of F-18 FDG in cervical lymph node metastasis not evidenced in *s*TSH exam. A 73-year-old male was diagnosed 9 years ago with a non-aggressive DTC subtype. He had multiple radioiodine doses (cumulative dose = 30.6 GBq = 827 mci) and rising sTg levels = 69 ng/ml. The *s*TSH F-18 FDG PET/CT trans axial A) PET B) CT and C) fused images show normal F-18 FDG biodistribution. The *e*TSH F-18 FDG PET/CT trans axial D) PET E) CT and F) Fused images demonstrated intense uptake in the same right cervical lymph node level IIa (SUV = 3.9). Histopathology confirmed a metastasis.Figure 1

The uptake was slightly higher in the *e*TSH FDG PET/CT scans (p = 0.4258) ([Table 8](#tbl8){ref-type="table"}). Probably due to these increase in uptake we demonstrated disease in additional three patients (kappa = 0.6087) ([Table 6](#tbl6){ref-type="table"}). Although, an increase in the mean quantity of cervical lymph node metastases was not noted under *e*TSH (p = 1.0) the number of cervical levels was higher when performed with eTSH (p = 0.1250) ([Table 7](#tbl7){ref-type="table"}).Table 8SUVmax values of the metastases in *s*TSH and *e*TSH F-18 FDG PET/CT studies.Table 8Sites of metastases*sTSH*\
F-18 FDG PET/CT\
Mean ± S.D.*e*TSH\
F-18 FDG PET/CT\
Mean ± S.D.p-valuesLocal recurrence9.3 ± 4.312.5 ± 9.3NCCervical LNs15.1 ± 22.211.8 ± 16.40.4258Distant LNs7.6 ± 2.67.2 ± 3.20.7500Lung8.2 ± 7.49.2 ± 8.11Bone8.7 ± 3.67.3 ± 1.7NCOther6.1 ± 0.05.2 ± 2.61[^10]

Distant lymph node metastases were identified in 20% of the patients in *s*TSH FDG PET/CT and in 27% of the *e*TSH FDG PET/CT scans (kappa = 0.8148) but the difference in the mean number of lymph node metastases between exams was not significant (p = 1.000) ([Table 7](#tbl7){ref-type="table"}). The mean SUVmax was slightly higher (although not significant) in the *e*TSH scan (p = 0.750) ([Table 8](#tbl8){ref-type="table"}).

3.3. Lung and bone metastases {#sec3.3}
-----------------------------

Lung metastases were found in 47% of the patients on both the *e*TSH and *s*TSH FDG PET/CT scans (kappa = 1.000). The intensity of uptake and the number of lesions were similar between scans (p = 1.000) (Tables [8](#tbl8){ref-type="table"} and [7](#tbl7){ref-type="table"}, respectively).

Bone metastases were identified in 13% of patients on both the *e*TSH and *s*TSH FDG PET/CT scan (kappa = 1.000). The differences among *s*TSH and *e*TSH FDG PET/CT for SUVmax values and the quantity of bone metastases identified was not calculable (N ≤ 2).

Metastases in other sites were identified in 13.3% patients in the *e*TSH FDG PET/CT scan and in 7% in the *s*TSH FDG PET/CT scan. Differences among *s*TSH and *e*TSH FDG PET/CT scans were also not calculable (N ≤ 2) for SUVmax values and for the quantity of metastases.

We found a trend in detecting higher total number of lesions (p = 0.3203) and higher total SUVmax (p = 0.0640) when the patients performed the exam under *e*TSH ([Figure 2](#fig2){ref-type="fig"}).Figure 2*e*TSH F-18 FDG PET/CT demonstrated an additional lymph node not evidenced by *s*TSH exam. A 60-year-old female was diagnosed 18 years ago with an aggressive DTC subtype. She had multiple radioiodine doses (cumulative dose = 25.9GBq = 700mCi) and signs of radioiodine refractory thyroid cancer (rising sTg levels = 16.7 ng/ml). The *s*TSH F-18 FDG PET/CT trans axial A) PET B) CT and C) Fused images show marked uptake in a right cervical lymph node level IIb (SUV = 5.3). The *e*TSH F-18 FDG PET/CT trans axial D) PET E) CT and F) Fused images demonstrated higher uptake (SUV = 6.5) in the same lymph node and an additional adjacent lymph node (SUV = 4.8) not evidenced on the *s*TSH F-18 FDG PET/CT. Histopathology confirmed both metastases.Figure 2

3.4. Patient management change {#sec3.4}
------------------------------

Prior to our investigation 60% of the RAIR patients had negative imaging studies. F-18 FDG PET/CT studies changed clinical management in 44% of patients. There was no difference in clinical management change when comparing *e*TSH with *s*TSH F-18 FDG PET/CT scans.

4. Discussion {#sec4}
=============

We demonstrated that the head-to-head comparison of the uptake pattern of F-18 FDG in radioiodine refractory dedifferentiated thyroid cancer under elevated and suppressed TSH levels does not show significant differences. We were able to demonstrate that in RAIR patients, F-18 FDG PET/CT imaging is a sensitive method to detect F-18 FDG-avid metastases regardless of TSH levels. Performing F-18 FDG PET/CT with either supressed or elevated TSH levels in patients with radioiodine-refractory thyroid cancer has been a matter of debate. Studies evaluating the influence of TSH serum levels in the uptake pattern of F-18 FDG has shown discrepant findings \[[@bib10], [@bib12], [@bib13], [@bib14], [@bib15], [@bib17], [@bib19]\]. TSH has been shown to increase F-18 FDG uptake in benign thyroid culture cells, supporting the rationale that F-18 FDG could have a higher detection rate in differentiated thyroid cancer metastases if F-18 FDG PET/CT images were performed under elevated TSH levels \[[@bib20], [@bib21]\]. However, the contrary was found in thyroid carcinoma cell lines; elevated TSH did not influence the uptake of F-18 FDG \[[@bib22]\].

Other studies have also demonstrated similar findings, with mean SUVmax and number of lesions bearing minimal or no difference between *e*TSH and *s*TSH levels \[[@bib12], [@bib13], [@bib14], [@bib15]\]. The advantage of our study was the ability to investigate all the patients under both conditions, and thus the uptake pattern of F-18 FDG and the number of lesions could be directly compared and influenced solely by TSH levels. Cervical and distant lymph node metastases were better identified in the *e*TSH FDG PET/CT scans, probably dur to increase in uptake although this higher uptake was not significant. The detection rate of *e*TSH FDG PET/CT scans were higher and identified cervical lymph node metastases in 67% *versus* 47% in the *s*TSH FDG PET/CT scans. This difference in detection rate could be noted, probably, due to the fact that three patients among the small total of fifteen patients were significant maybe; in a greater number of patients, these differences would not appear.

Furthermore, there was a trend towards detecting a higher total number of lesions and higher SUVmax values with *e*TSH and on a per-patient based analysis; 20% of our population had additional sites of metastases detected by *e*TSH FDG PET/CT, although again these differences were not significant.

We found F-18 FDG avid lesions in 80% of our patients with high specificity (*s*TSH = 99%; eTSH = 98%) and accuracy (sTSH = 87%; eTSH = 90%). F-18 FDG PET/CT performed with *e*TSH presented higher sensitivity for cervical lymph nodes when compared to *s*TSH (75% *vs* 50%) and distant LN (80% *vs* 60%). This might be due to the increase in mean Tg levels (1226.1 ng/mL *vs* 892.9 ng/mL; p = 0.001). However, not all of our patients presented high levels of suppressed Tg; some presented progressively increasing levels of anti-Tg antibodies and thefore were also included in our study. In the remaining 20% of patients where F-18 FDG avid metastases were not detected, the mean *s*Tg levels of these patients was 6.3 ng/ml. This findings support studies showing that F-18 FDG PET/CT sensitivity increases according to increase in Tg levels, especially when above 10 ng/ml, with sensitivities ranging from 28.6% (with Tg levels 2--5 ng/ml) up to 85.7% (with Tg levels ≥20 ng/ml) \[[@bib15], [@bib23], [@bib24], [@bib25], [@bib26]\]. Two patients out of three (66%) of our study with a negative F-18 FDG PET/CT presented stable disease confirming the prognostic role of F-18 FDG PET/CT that has also been described in other studies \[[@bib27]\].

Age is related with a higher risk disease and worst prognosis; a positive F-18 FDG PET indicates a higher risk of progression in patients above 45 years \[[@bib28]\]. In our study, the elderly (above 60 years of age) patient group (53%), presented a more aggressive behavior, with higher Tg levels (1559 ng/mL *vs* 934 ng/mL, respectively). The elderly group of patients also presented higher SUVmax values for all sites compared to the younger group (local recurrence = 12.3 *vs* 6.2; cervical lymph node metastases = 12.8 *vs* 3.8; distant lymph node metastases = 8.7 *vs* 5.3; lung metastases = 6.3 *vs* 4.8; bone metastases = 11.2 *vs* 6.1, respectively).

The detection of new lesions with F-18 FDG PET/CT can change clinical management in 21%--51% of patients \[[@bib14], [@bib19], [@bib29]\]. Prior to our investigation 60% of our patients had negative imaging studies despite signs of RAIR. F-18 FDG PET/CT studies changed clinical management in 44% of them. No significant difference in management change was observed between F-18 FDG PET/CT studies with *e*TSH or *s*TSH levels.

One limitation of our study was the small number of patients. RAIR patients are rare, account for approximately 2% of a population of patients with DTC \[[@bib5], [@bib6]\]. One multicentric study was able to analyze only 33 patients while another study, with 5163 DTC, only 2.2% had the RAIR profile.This limitation was overcome by its strength, as the head-to-head F-18 FDG PET/CT images of the same patient were compared in two different conditions (*e*TSH and *s*TSH) and thus no other variables could have interfered, as there was no signs of progression between exams. Another limitation was the fact that our patient population had to have levothyroxine withdrawal. Unfortunately, the use of recombinant TSH (Thyrogen®) was not possible, due to economic limitations in our public hospital.

5. Conclusion {#sec5}
=============

F-18 FDG PET/CT scans impacts in clinical management change in radioiodine refractory dedifferentiated thyroid cancer patients. However, the head-to-head comparison of the uptake pattern was not different among elevated and supressed TSH levels, even though the F-18 FDG uptake is higher with elevated TSH levels.

The role of hormonal withdrawal in radioiodine refractory dedifferentiated thyroid cancer patients prior to an F-18 FDG PET/CT scan may be unnecessary. More studies with a larger number of patients, with a head-to-head comparison, as we have undertaken, are necessary to confirm our findings.
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[^1]: F = Female; M = Male; NA = Non-aggressive; A = Aggressive; TT = Total Thyroidectomy + Central node dissection; UND = Total Thyroidectomy + Central dissection + Unilateral neck dissection; BND = Total Thyroidectomy + Central dissection + Bilateral dissection. ∗ = patients with increased Tg antibody levels.

[^2]: *s*TSH = suppressed TSH; *e*TSH = elevated TSH; ∗p \< 0.05. Bold highlights the values that are significant.

[^3]: Obs: Each patient performed the exam in a different day according to last F-18 FDG PET/CT study scheduled.

[^4]: *s*TSH = suppressed TSH; ∗p \< 0.05.

[^5]: LR: Local Recurrence; CLn = Cervical Lymph node metastases; DLn = Distant Lymph node metastases; NI = Not identified.

[^6]: *s*TSH = suppressed TSH; *e*TSH = elevated TSH.

[^7]: *s*TSH = suppressed TSH; *e*TSH = elevated TSH; ∗p \< 0.05.

[^8]: LNs = lymph nodes; *s*TSH = suppressed TSH; *e*TSH = elevated TSH; ∗p \< 0.05.

[^9]: LNs = lymph nodes; *s*TSH = suppressed TSH; *e*TSH = elevated TSH; ∗p \< 0.05; NC = not calculable (N ≤ 2).

[^10]: *s*TSH = suppressed TSH; *e*TSH = elevated TSH. LNs = lymph nodes; ∗p \< 0.05, NC = not calculable (N ≤ 2).
